Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.33, read 2026-11-05
Ethical passes the values gate
Price170.62 USD
Fair value176.99
Ethical score70.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup163.98+4.0% to today ✓Distribution gives way to Markup after a 10% rise in 9 days
2026-10-02Read Distribution149.38+14.2% to today Markup gives way to Distribution after a 22% rise in 13 weeks
2026-07-02Read Markup122.56+39.2% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Guidewire Software Inc holds its Distribution at $170.62. The statistical read favours the buyers, held for 39 days.
As held on the ledger · 2026-11-04
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 39 days
Price at the screen
$170.62
Valuation
115.95 trailing · 35.36 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.03
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
26.30%
Below 33%
Interest-bearing debt is just 26.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
12.27%
Below 33%
Cash held in interest-bearing accounts and securities is 12.3% of assets, under the one-third limit.
Pass
Receivables
30.82%
Below 49%
Money owed to the company is 30.8% of assets, under the 49% limit.
Pass
Revenue purity
4.71%
Below 5%
Only 4.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Guidewire Software clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 26%, inside the ~33% line, and interest is about 5% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when GWRE's ethical verdict changes
Today GWRE passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades at roughly a 4% discount to our $176.99 fair value, narrow competitive moat, 15.30% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 3.6% discount to the base estimate.
Where our models see it going: fair-value estimate $176.99, with a range of $153.00 to $203.54, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Insurance software that insurers cannot ditch
Picture a claims team at a midsize US insurer trying to switch systems mid storm season. Guidewire sits underneath that daily grind with its PolicyCenter and ClaimCenter tools, now shifting more customers onto the cloud version. Revenue is climbing 27 percent, the business clears an 11 percent profit margin and posts 12 percent ROE, yet the shares trade at 36.6 times forward earnings with only a 2 percent margin of safety to our fair value.
That narrow moat and clean ethical screen keep the name on the list, but the numbers do not scream opportunity. Analysts like the story and cluster around a 201 target, yet the valuation already prices in most of the visible growth and leaves little room for the hiccups that hit software rollouts.
High multiples on a single vertical also mean any slowdown in P&C spending or a longer cloud migration cycle would hit the multiple first. The setup stays steady rather than compelling. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GWRE trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup$162.59-14.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 14.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 54%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (13 analysts) rates it buy, with a mean price target of $207. Insiders have been net sellers over the past quarter.
2026-10-25Markup$189.00+7.5%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 54%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (13 analysts) rates it buy, with a mean price target of $207. Insiders have been net sellers over the past quarter. Since the last review it dropped out of the Titan Ethical 500.
2026-10-18Markup$175.77+7.2%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 54%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (13 analysts) rates it buy, with a mean price target of $207. Insiders have been net sellers over the past quarter.
2026-10-11Markup · changed$163.98+9.8%Entry 14
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 54%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (13 analysts) rates it buy, with a mean price target of $207. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 22.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 54%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (13 analysts) rates it buy, with a mean price target of $207. Insiders have been net sellers over the past quarter. Since the last review it entered the Titan Ethical 500; its composite score rose.
2026-09-03Markup$192.76+9.8%Entry 12
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 54%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (13 analysts) rates it buy, with a mean price target of $207. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-02Markup$175.59+0.0%Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 54%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (13 analysts) rates it buy, with a mean price target of $207. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-01Markup$175.59+0.0%Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 54%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (13 analysts) rates it buy, with a mean price target of $207. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-31Markup$175.59+0.0%Entry 9
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 54%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (13 analysts) rates it buy, with a mean price target of $207. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-30Markup$175.59+0.0%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 54%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (13 analysts) rates it buy, with a mean price target of $207. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
